Fibrocell Science, Inc.s LAVIV (azficel-T) Available to Adult Women Searching for the Latest Beauty Breakthrough
From New York to Los Angeles and Miami, Fibrocell Science, Inc.s
(OTCBB:FCSC) LAVIV (azficel-T) has been making headlines as one of the
latest treatments to hit the aesthetics market. Latinas place great
importance on appearance 69 percent report that wearing makeup and
looking good is essential versus 46 percent of non-Latinas, according to
a 2011 Univision study. Now with LAVIV, a customized injectable
treatment, Latina adults with moderate to severe smile line (nasolabial
fold) wrinkles can improve the look of these wrinkles by using their own
living, cultured, collagen-producing fibroblast cells.
Hispanic women are known for being early adopters of ground-breaking
beauty and personal care treatments, said Julio M. Gallo, MD, FACS,
medical director and facial plastic surgeon at The MIAMI Institute for
Age Management in Miami. I believe LAVIV is a cutting edge
treatment that Latinas across the country should know about. It
helps
improve a patients outer beauty from within using state of the art
technology to treat smile line wrinkles in a very customized way. I
dont think theres anything quite like it on the market.
The patented technology behind LAVIV is an advanced process that
extracts a persons fibroblast cells from a small skin sample taken from
behind the ear and multiplies them in the Fibrocell Science lab. In
normal skin, fibroblasts are responsible for producing collagen, which
gives skin its tone and structure. LAVIV is the resulting
formulation of a persons own living, cultured fibroblast cells, which
is then injected into moderate to severe smile lines. Each persons
formulation of LAVIV is unique because it is made from their own
cells.
According to the American Society for Aesthetic Plastic Surgery,
Hispanics lead all minority groups in cosmetic surgery, and there has
been a 49 percent increase in procedures among Hispanics since 2000. In
2009, about 1.4 million Latinos underwent cosmetic procedures, from
surgery to injections; a threefold increase from nine years earlier,
according to the American Society of Plastic Surgeons.
For more information on LAVIV, including Contraindications,
Warnings and Precautions and Adverse Reactions, please see the
accompanying full Prescribing Information. To find a certified physician
in your area, please visit www.mylaviv.com.
LAVIV (azficel-T) is an autologous cellular product indicated
for improvement of the appearance of moderate to severe nasolabial fold
wrinkles in adults. The safety and efficacy of LAVIV for areas
other than nasolabial folds have not been established. The efficacy of LAVIV
beyond six months has not been established.
Important Safety Information About LAVIV (azficel-T)
LAVIV is made especially for you from your own skin cells. Using
someone elses cells can cause a serious reaction. Do not let anyone
else use your LAVIV. Prior to injection, confirm with your
physician that your information on the LAVIV vial is correct.
Your health care provider will help you to decide whether you are a
candidate for LAVIV and may help you avoid some of the adverse
reactions from LAVIV. Before getting LAVIV, tell your
healthcare provider if you have any medical problems including allergic
reactions to any drugs or food, bleeding disorders or take
blood-thinning medicines like aspirin, ibuprofen, or Coumadin® (warfarin
sodium), keloids or excessive scarring, skin cancer or any malignancy,
genetic disorders affecting your skin, immune problems or take medicines
that affect your immune system, or any other illness or medical problem.
Please tell your healthcare provider if you are allergic to the
antibiotics amphotericin or gentamicin, bovine materials (products made
from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV if
you have a skin infection on your face because LAVIV treatment
can make the infection worse.
The most common side effects of LAVIV are at the injection-site,
including redness, bruising, swelling, pain, bleeding, lumps,
irritation, and itchiness. In clinical trials with LAVIV, most
injection-site adverse reactions resolved within one week and most
required no treatment. The full Prescribing Information for LAVIV
includes additional warnings about adverse reactions that occurred in
less than 1% of patients following LAVIV treatment in clinical trials.
Talk to your healthcare provider about these warnings.
Only healthcare providers who have completed a Fibrocell-approved
training program should administer LAVIV.
Please see the full Prescribing Information for LAVIV Contraindications,
Warnings, Precautions and Adverse Reactions at www.mylaviv.com.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTCBB:FCSC.OB) is a cell therapy company
focused on the development of autologous (personalized) cell therapies
for aesthetic, medical and scientific applications. Fibrocell Science is
committed to advancing the scientific, medical and commercial potential
of autologous skin and tissue, as well as its innovative cellular
processing technology and manufacturing excellence. For additional
information, please visit www.fibrocellscience.com.
